ApicHope Pharmaceutical Group Co., Ltd.
↗Guangzhou, China
ApicHope Pharmaceutical Group is a Chinese innovative biopharmaceutical company focused on the research, development, production, and sales of pharmaceuticals. The company specializes in pediatric medications and chronic disease treatments, maintaining a comprehensive industrial chain that includes R&D centers and digital production bases compliant with international standards.
Founded in 2002 and listed on the Shenzhen Stock Exchange (300723.SZ) in 2017, the company has expanded its portfolio significantly, holding numerous drug registration approvals. It actively invests in innovative drug platforms, including high-end pediatric formulations and chronic disease treatments, with a strong focus on global clinical development and international market standards.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Pediatrics and Chronic Disease Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$500M
Founded:2002
Ownership:public
Status:operating
STOCK
Exchange:Shenzhen Stock Exchange
Ticker:300723.SZ
Market Cap:$2.02B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Chemical drugs, Herbal medicine
Active Trials:35
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:South China Vaccine Corporation
Key Partnerships:Degron Therapeutics (Investment/Collaboration)
COMPETITION
Position:Emerging
Competitors:Akums, Jubilant Life Sciences, Unither
LINKS
Website:gdyph.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ApicHope Pharmaceutical Group Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ApicHope Pharmaceutical Group Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.